Researchers from the University of Cambridge and the Institute of Cancer Research in London have identified significant gaps in how England’s National Institute for Health and Care Excellence (Nice) guidelines identify women at elevated risk of breast cancer. According to an analysis published in the British Journal of Cancer, the current referral criteria used by general practitioners miss up to 95% of women under 50 who will develop breast cancer within a decade.
The disparity stems largely from the Nice guidelines’ heavy reliance on family history as the primary risk indicator. The study found that approximately 73% of women under 50 who develop breast cancer within 10 years have no family history of the disease, making them invisible under existing assessment protocols. Researchers compared the current guidelines against an alternative risk assessment system called Boadicea, developed by Cambridge and funded by Cancer Research UK, which identified eight times as many women in the age group at higher risk of developing the disease.
Boadicea evaluates a broader range of factors beyond family history, including reproductive history, lifestyle factors, and genetic information. Experts contend that earlier identification of high-risk women would enable doctors to offer additional screening options or preventive treatments before disease development, improving outcomes when intervention is possible. Dr Juliet Usher-Smith of Cambridge stated that better identification of women at highest risk is necessary to enable earlier intervention with more treatment options available.
However, implementing expanded risk assessment systems presents practical and resource challenges. Prof Montserrat García-Closas of the ICR noted that while the current Nice criteria are simpler to implement, comprehensive risk assessment including genetic testing would place substantial burden on healthcare resources. Officials at Breast Cancer Now, which supported the study, emphasized that any guideline changes must be accompanied by adequate investment in family history services to ensure fair implementation across the NHS.
A Nice spokesperson acknowledged the study’s findings and the potential of multifactorial risk models but stated that current evidence does not warrant immediate changes to existing familial breast cancer guidance. The organization indicated it remains open to reviewing updated evidence as more data on feasibility and clinical outcomes becomes available.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI